c104951.htm - Prepared by Imprima

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

June 1, 2011

________________

 

        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

Company Announcement

31 May 2011

Total number of voting rights and share capital in Novo Nordisk A/S as of 31 May 2011

 

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of the month where changes have occurred.

 

Referring to Company Announcement no 26/2011 dated 2 May 2011, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 31 May 2011.

 

 

Number of shares

Nominal value

Number of votes

 

(nominal value DKK 1)

(DKK)

 

 

 

 

 

A shares

107,487,200

107,487,200

107,487,200,000

B shares

472,512,800

472,512,800

47,251,280,000

 

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

 

Company Announcement no 34 / 2011

Page 1 of 2

 

Novo Nordisk A/S

Corporate
Communications

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 2314

Internet:

novonordisk.com

CVR Number:

24256790

 


 

 

 

Further information:

 

 

 

Media:

Investors:

 

 

Outside North America:

Klaus Bülow Davidsen

Anne Margrethe Hauge

Tel: (+45) 4442 3176

Tel: (+45) 4442 3450

klda@novonordisk.com

amhg@novonordisk.com

 

 

 

 

Jannick Lindegaard

 

Tel: (+45) 4442 4765

 

jlis@novonordisk.com

 

 

In North America:

 

Ken Inchausti

Frank Daniel Mersebach

Tel: (+1) 609 514 8316

Tel: (+45) 4442 0604

kiau@novonordisk.com

fdni@novonordisk.com

 

 

Company Announcement no 34 / 2011

Page 2 of 2

 

Novo Nordisk A/S

Corporate
Communications

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 2314

Internet:

novonordisk.com

CVR Number:

24256790

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 1, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer